Besides being a form of therapeutics to fight breast and ovarian cancer in DSBR-deficient patients, PARP1 inhibitors are also used in cardiac diseases and infection to suppress overexpressed PARP1. This evidence concerns the gene PARP1 and ovarian carcinoma.